Free Trial
NASDAQ:ENTA

Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis

Enanta Pharmaceuticals logo
$6.56 -0.42 (-6.02%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$6.56 0.00 (-0.08%)
As of 07/11/2025 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Enanta Pharmaceuticals Stock (NASDAQ:ENTA)

Key Stats

Today's Range
$6.50
$7.04
50-Day Range
$5.05
$7.97
52-Week Range
$4.09
$17.24
Volume
189,465 shs
Average Volume
281,925 shs
Market Capitalization
$140.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Moderate Buy

Company Overview

Enanta Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
78th Percentile Overall Score

ENTA MarketRank™: 

Enanta Pharmaceuticals scored higher than 78% of companies evaluated by MarketBeat, and ranked 332nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Enanta Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Enanta Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Enanta Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Enanta Pharmaceuticals are expected to decrease in the coming year, from ($4.65) to ($4.98) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Enanta Pharmaceuticals is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Enanta Pharmaceuticals is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Enanta Pharmaceuticals has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Enanta Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    12.19% of the float of Enanta Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Enanta Pharmaceuticals has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Enanta Pharmaceuticals has recently decreased by 3.20%, indicating that investor sentiment is improving.
  • Dividend Yield

    Enanta Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Enanta Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.19% of the float of Enanta Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Enanta Pharmaceuticals has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Enanta Pharmaceuticals has recently decreased by 3.20%, indicating that investor sentiment is improving.
  • News Sentiment

    Enanta Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added Enanta Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Enanta Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.89% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Enanta Pharmaceuticals' insider trading history.
Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENTA Stock News Headlines

Enanta Pharmaceuticals, Inc. (ENTA) - Yahoo Finance
Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
See More Headlines

ENTA Stock Analysis - Frequently Asked Questions

Enanta Pharmaceuticals' stock was trading at $5.75 at the beginning of 2025. Since then, ENTA stock has increased by 14.1% and is now trading at $6.56.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) issued its quarterly earnings data on Monday, May, 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.04) by $0.02. The biotechnology company earned $14.93 million during the quarter, compared to analyst estimates of $15.96 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 79.83% and a negative net margin of 149.57%.

Top institutional shareholders of Enanta Pharmaceuticals include Assenagon Asset Management S.A. (0.50%), Wealth Enhancement Advisory Services LLC (0.05%) and Farther Finance Advisors LLC (0.03%). Insiders that own company stock include Jay R Luly, Yat Sun Or, Paul J Mellett, Brendan Luu, Tara Lynn Kieffer, Scott T Rottinghaus and Terry Vance.
View institutional ownership trends
.

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enanta Pharmaceuticals investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/12/2025
Today
7/12/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENTA
CIK
1177648
Employees
160
Year Founded
N/A

Price Target and Rating

High Price Target
$24.00
Low Price Target
$10.00
Potential Upside/Downside
+174.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$116.04 million
Net Margins
-149.57%
Pretax Margin
-153.41%
Return on Equity
-79.83%
Return on Assets
-26.65%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.29
Quick Ratio
5.29

Sales & Book Value

Annual Sales
$67.64 million
Price / Sales
2.07
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.08 per share
Price / Book
1.08

Miscellaneous

Outstanding Shares
21,380,000
Free Float
18,408,000
Market Cap
$140.25 million
Optionable
Optionable
Beta
0.84

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:ENTA) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners